Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.80 USD
+0.26 (7.34%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.79 -0.01 (-0.26%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Pyxis Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -73.79 | -120.72 | -75.98 | -12.83 | NA |
Depreciation/Amortization & Depletion | -2.86 | 0.71 | 0.65 | 0.47 | NA |
Net Change from Assets/Liabilities | -11.66 | 4.50 | 6.68 | 1.87 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 17.61 | 26.17 | 33.33 | 0.41 | NA |
Net Cash From Operating Activities | -70.71 | -89.34 | -35.33 | -10.08 | NA |
Property & Equipment | -6.73 | -6.40 | -0.54 | -1.48 | NA |
Acquisition/ Disposition of Subsidiaries | 6.66 | 0.00 | 0.00 | 0.00 | NA |
Investments | -104.78 | 0.00 | -0.05 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | -0.05 | 0.00 | NA |
Net Cash from Investing Activities | -104.85 | -6.40 | -0.59 | -1.48 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.37 | 0.18 | 304.04 | 0.04 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.45 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 5.93 | 0.18 | 304.04 | 0.04 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -169.63 | -95.55 | 268.13 | -11.53 | NA |
Cash at Beginning of Period | 180.77 | 276.32 | 8.19 | 19.72 | NA |
Cash at End of Period | 11.14 | 180.77 | 276.32 | 8.19 | NA |
Diluted Net EPS | -1.85 | -3.65 | -8.95 | NA | NA |
Fiscal Year End for Pyxis Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -3.26 | -73.79 | -58.19 | -35.14 | -19.24 |
Depreciation/Amortization & Depletion | -0.17 | -2.86 | -2.11 | -1.15 | -0.42 |
Net Change from Assets/Liabilities | -21.77 | -11.66 | -9.36 | -10.45 | -12.21 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.48 | 17.61 | 14.20 | 8.87 | 5.03 |
Net Cash From Operating Activities | -20.71 | -70.71 | -55.46 | -37.87 | -26.84 |
Property & Equipment | -0.24 | -6.73 | -6.73 | -6.67 | -4.41 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 6.66 | 6.66 | 0.00 | 0.00 |
Investments | -18.26 | -104.78 | -115.01 | -114.98 | -94.99 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -18.50 | -104.85 | -115.08 | -121.65 | -99.39 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 57.71 | 6.37 | 6.35 | 6.13 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.20 | -0.45 | -0.39 | 0.00 | 0.00 |
Net Cash from Financing Activities | 57.51 | 5.93 | 5.95 | 6.13 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 18.30 | -169.63 | -164.58 | -153.40 | -126.23 |
Cash at Beginning of Period | 11.14 | 180.77 | 180.77 | 180.77 | 180.77 |
Cash at End of Period | 29.44 | 11.14 | 16.19 | 27.37 | 54.53 |
Diluted Net EPS | -0.06 | -0.34 | -0.56 | -0.41 | -0.54 |